Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 1744-22-5 Chemical Structure| 1744-22-5

Structure of Riluzole
CAS No.: 1744-22-5

Chemical Structure| 1744-22-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Riluzole is an antagonist of glutamate that used as an anticonvulsant. It can prolong the survival of patients with amyotrophic lateral sclerosis.

Synonyms: PK 26124; RP-54274; Riluzole, Rilutek, PK 26124, PK26124, PK-26124, RP 54274, RP54274

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Kim, Jaejeong ; Kang, Changyu ; Jung, Yunjin ;

Abstract: Purpose: In our previous study, (RLZ) azo-linked to (RAS) was prepared as a colon-targeted RLZ prodrug against rat colitis. However, was not a satisfactory colon-targeted prodrug because of its non-negligible systemic absorption, leading to low colonic delivery efficiency and the ability to limit the systemic absorption of RLZ. This study aimed to improve the colon specificity and anticolitic activity of . Methods: (SA) was conjugated with the acidic amino acids (Asp) and (Glu) and subsequently azo-coupled with to yield Asp-conjugated (RAS-Asp) and Glu-conjugated (RAS-Glu). Results: Amino acid-conjugated lowered the distribution coefficient and cell permeability of while exhibiting a release profile of RLZ similar to that of in the cecal contents. Upon oral gavage, amino acid-conjugated delivered a larger amount of RLZ to the cecum than . The ability of amino acid-conjugated to limit the systemic absorption of RLZ was greater than that of . No significant differences were observed in the colon-specific performance between RAS-Asp and RAS-Glu. In a DNBS-induced rat colitis model, amino acid-conjugated was more effective than in ameliorating colonic damage and inflammation and modulating the anti-inflammatory GSK3β-IL-10 pathway in the inflamed colon, without a significant difference between RAS-Asp and RAS-Glu. Conclusion: Conjugation of acidic amino acids with improved the colon specificity, anticolitic activity, and safety of . N-Salicyloyl acidic amino acids may act as high-performance colon-specific promiety for a candidate drug modifiable to a colon-targeted prodrug with an azo bond as a colon-specific link.

Keywords: ; Colon-targeted prodrug ; Colitis ; Acidic amino acids ; High performance colon-specific promoiety

Purchased from AmBeed: ; ; ;

Kim, Jaejeong ; Kang, Changyu ; Yoo, Jin-Wook ; Yoon, In-Soo ; Jung, Yunjin ;

Abstract: In our previous study, riluzole azo-linked to salicylic acid (RAS) was prepared as a colon-targeted prodrug of riluzole (RLZ) to facilitate the repositioning of RLZ as an anticolitic drug. RAS is more effective against rat colitis than RLZ and sulfasalazine, currently used as an anti-inflammatory bowel disease drug. The aim of this study is to further improve colon specificity, anticolitic potency, and safety of RAS. N-succinylaspart-1-ylRLZ (SAR) and N-succinylglutam-1-ylRLZ (SGR) were synthesized and evaluated as a ""me-better"" colon-targeted prodrug of RLZ against rat colitis. SAR but not SGR was converted to RLZ in the cecal contents, whereas both conjugates remained intact in the small intestine. When comparing the colon specificity of SAR with that of RAS, the distribution coefficient and cell permeability of SAR were lower than those of RAS. In parallel, oral SAR delivered a greater amount of RLZ to the cecum of rats than oral RAS. In a DNBS-induced rat model of colitis, oral SAR mitigated colonic damage and inflammation and was more potent than oral RAS. Moreover, upon oral administration, SAR had a greater ability to limit the systemic absorption of RLZ than RAS, indicating a reduced risk of systemic side effects of SAR. Taken together, SAR may be a "me-better" colon-targeted prodrug of RLZ to improve the safety and anticolitic potency of RAS, an azo-type colon-targeted prodrug of RLZ.

Keywords: riluzole ; colon-targeted drug delivery ; colitis ; prodrug ; N-succinylated acidic amino acids

Purchased from AmBeed: ; ; ;

Alternative Products

Product Details of Riluzole

CAS No. :1744-22-5
Formula : C8H5F3N2OS
M.W : 234.20
SMILES Code : NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
Synonyms :
PK 26124; RP-54274; Riluzole, Rilutek, PK 26124, PK26124, PK-26124, RP 54274, RP54274
MDL No. :MFCD00210213
InChI Key :FTALBRSUTCGOEG-UHFFFAOYSA-N
Pubchem ID :5070

Safety of Riluzole

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H300
Precautionary Statements:P264-P270-P301+P310+P330-P405-P501
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Target
  • NMDA receptor

  • Sodium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
Astrocytes 1 μM 24 h To investigate the effect of Riluzole on CT-1 secretion by astrocytes, results showed that Riluzole significantly increased CT-1 secretion. PMC4864959
Schwann cells 1 μM 24 h To investigate the effect of Riluzole on CT-1 secretion by Schwann cells, results showed that Riluzole significantly increased CT-1 secretion. PMC4864959
Pancreatic cancer cell lines (PANC-1, AsPC-1, Hs 766T, MIA PaCa-2) 0-40 µM 72 h Riluzole inhibited cell viability and colony formation in pancreatic cancer cell lines (AsPC-1, PANC-1, MIA PaCa-2) and induced apoptosis. PMC9246955
Pancreatic cancer stem cells (CSCs) 0-40 µM 72 h Riluzole inhibited cell viability and colony formation in pancreatic cancer stem cells and induced apoptosis. PMC9246955
Human pancreatic normal ductal epithelial (HPNE) cells 0-40 µM 72 h Riluzole had no effect on the viability of human pancreatic normal ductal epithelial (HPNE) cells. PMC9246955
Neural Progenitor Cells (NPCs) 200 µM 48 h To investigate the effect of Riluzole on PA-induced apoptosis, Riluzole protected NPCs from lipotoxicity-induced cell death by regulating ZnT3 expression and maintaining zinc homeostasis. PMC11538679
Human Cerebral Organoids 5 µM 5 days To investigate the effect of Riluzole on WFS1 deficiency-induced apoptosis, Riluzole protected cerebral organoids from lipotoxicity-induced cell death by regulating ZnT3 expression and reducing zinc levels. PMC11538679
UOK115 renal carcinoma cells 25 μM 96 h To evaluate the effect of Riluzole on renal carcinoma cell proliferation, results showed a reduction in UOK115 cell proliferation by about 20%. PMC3910169
UOK117 renal carcinoma cells 25 μM 96 h To evaluate the effect of Riluzole on renal carcinoma cell proliferation, results showed a reduction in UOK117 cell proliferation by about 50%. PMC3910169
C8161 cells 25 µM 24 h Riluzole enhanced the lethal effects of ionizing radiation, with a 48% reduction in cell survival at 2Gy and a 19% reduction at 4Gy. PMC3070864
UACC903 cells 25 µM 24 h Riluzole enhanced the lethal effects of ionizing radiation, with a significant reduction in cell survival at 2Gy and 4Gy. PMC3070864
UACC930 cells 25 µM 24 h Riluzole had no significant effect on the survival of UACC930 cells. PMC3070864
CPVT ventricular cardiomyocytes 10 Μm Riluzole significantly decreased the frequency of ISO-promoted DCRs PMC5065245

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice TETS-induced status epilepticus model Intraperitoneal injection 10 mg/kg Single dose To investigate the effect of Riluzole in the TETS-induced status epilepticus model, results showed that pretreatment with Riluzole prevented lethal seizures in mice. PMC6910080
Mice SOD1-G93A ALS model Administered via chow 125 mg/kg Started at 100 days of age and continued for the lifespan of all mice Riluzole in combination with Elacridar significantly extended survival in ALS mice and improved behavioral measures, including muscle function, slowing disease progression. PMC4284125
C57BL/6J mice C57BL/6J mice Drinking water 100 μg/ml Continuous administration for 15 or 30 days, followed by a 15-day washout period, then additional administration for 6 or 15 days To investigate the effect of Riluzole on CT-1, GDNF, and BDNF levels in the spinal cord of mice, results showed that discontinuous administration maintained elevated CT-1 levels but had inconsistent effects on GDNF and BDNF. PMC4864959
Mice 3xTg AD mouse model Drinking water 12.5 mg/kg Daily administration for 20 weeks Riluzole treatment significantly improved cognitive function, reduced Aβ plaque deposition, tau hyperphosphorylation, astrocyte activation, and neuronal loss, and exerted neuroprotective effects by modulating Glu and GABA metabolism. PMC11726951
KPC mice Pancreatic cancer model Intraperitoneal injection 20 mg/kg Five days a week for 12 weeks Riluzole inhibited pancreatic cancer growth and development in KPC mice, reduced pancreas weight, and significantly inhibited numbers of PanIN 1 and 2 lesions. PMC9246955
Mice High-fat diet-induced obesity and depression model Oral 50 mg/kg Once daily for 2 months To investigate the effect of Riluzole on high-fat diet-induced obesity and depression, Riluzole alleviated obesity and depressive-like behaviors by regulating ZnT3 expression and reducing zinc levels. PMC11538679
Nude mice C8161 xenograft model Oral gavage 10 mg/kg Daily for 25 days The combination of riluzole and ionizing radiation significantly inhibited tumor growth and increased DNA damage in tumor cells. PMC3070864
Mice CPVT model Intraperitoneal injection 15 mg/kg Single dose Pre-treatment with Riluzole significantly reduced the incidence of arrhythmias and ventricular tachycardia in CPVT mice during catecholamine challenge PMC5065245

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03359538 Amyotrophic Lateral Sclerosis Phase 2 Recruiting September 19, 2019 Italy ... More >> Centro Sla, Irccs A.O.U. S.Martino Ist, Genova Not yet recruiting Genova, Italy Contact: Claudia Caponnetto, MD          Centro Clinico Nemo, Fondazione Serena Onlus, Milano Not yet recruiting Milano, Italy Contact: Christian Lunetta, MD          Centro Sla, Irccs Fondazione Salvatore Maugeri, Milano Not yet recruiting Milano, Italy Contact: Kalliopi Marinou, MD          Centro Sla, Irccs Istituto Carlo Besta, Milano Not yet recruiting Milano, Italy Contact: Eleonora Dalla Bella, MD          Centro Sla, Ospedale Civile S. Agostino Estense, A.O.U. Modena Recruiting Modena, Italy, 41126 Contact: Jessica Mandrioli, MD    +390593961722       Centro Sla, A.O.U. Maggiore Della Carita', Novara Not yet recruiting Novara, Italy Contact: Letizia Mazzini, MD          Centro Sla, Universita' Di Padova Not yet recruiting Padova, Italy Contact: Gianni Sorarù, MD          Centro Sla, Universita' Di Torino Not yet recruiting Torino, Italy Contact: Adriano Chiò, Prof. Less <<
NCT01378676 Amyotrophic Lateral Sclerosis Phase 2 Completed - United States, California ... More >> California Pacific Medical Center San Francisco, California, United States, 94115 United States, Florida Mayo Florida Jacksonville, Florida, United States, 32224 United States, Kansas University of Kansas Kansas City, Kansas, United States, 06053 United States, Maryland Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, New York Columbia University Medical Center New York, New York, United States, 10032 SUNY Upstate Medical Center Syracuse, New York, United States, 13210 United States, North Carolina Carolinas Neuromuscular ALS-MND Center Charlotte, North Carolina, United States, 28207 United States, Pennsylvania Penn State Hershey Medical Center Hershey, Pennsylvania, United States, 17033 Drexel University College of Medicine Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT00560287 Amyotrophic Lateral Sclerosis ... More >> Chronic Respiratory Failure Less << Phase 4 Unknown August 2010 Italy ... More >> Fondazione S.Maugeri Recruiting Pavia, Italy, 27100 Contact: Stefano Nava, md    o3825921    snava@fsm.it    Contact: Stefano Nava, md    03825921    snava@fsm.it    Respiratory Unit FSM Not yet recruiting Pavia, Italy, 27100 Contact: Stefano Nava, md    0382 592 ext 806    snava@fsm.it    Contact: Francesco Fanfulla, MD    0382 592 ext 815    ffanfulla@fsm.it    Principal Investigator: Stefano Nava, MD Less <<
NCT00753571 Amyotrophic Lateral Sclerosis Phase 2 Unknown October 2010 China, Beijing ... More >> Dongsheng Fan, MD; Liping Wang,MD Recruiting Beijing, Beijing, China, 100191 Contact: Dongsheng Fan MD Fan, Docter    +861082265250 ext 0    chinaals@gmail.com;dsfan@sina.com ;    Contact: Liping Wang MD Wang, doctor    +8613810002694    chinaals@gmail.com;dianer@126.com Less <<
NCT00877604 Amyotrophic Lateral Sclerosis Phase 2 Completed - Italy ... More >> Fondazione IRCCS Istituto neurologico Carlo Besta Milan, Italy, 20133 Less <<
NCT00877604 - Completed - -
NCT03500289 Multiple Sclerosis ... More >> Fatigue Less << Phase 1 Phase 2 Recruiting September 1, 2019 United States, Maryland ... More >> Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Bridget Morris, BSN, RN    443-287-9998    bmorri25@jhmi.edu Less <<
NCT00694941 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 2 Completed - Belgium ... More >> Prof. Maloteaux, UCL Saint-Luc Brussels, Belgium Prof. Wim Robberecht, UZ Leuven Leuven, Belgium France Prof. Alain Destee, Hopital Roger Salengro - Clinique Neurologique, Neurologie A Lille Cedex, France Prof. Philippe Couratier, Hopital Duruytren Limoges Cedex, France Prof. Jan Pouget, Hopital de la Timone Marseille, France Prof. William Camu, Hopital de Chauliac Montpellier cedex 5, France Prof. Claude Desnuelle, Hopital 1-Archet 1 Nice cedex 3, France Prof. Vincent Meininger, Hopital LaPitie Salpetriere Paris, France Germany Dr. Thomas Meyer, Charite Campus Virchow, ALS Ambulanz Berlin, Germany Prof. Torsten Grehl, Neurologische Ambulanz Universitatsklinik Bergmannsheil Bochum, Germany Professor Dieter Heuss, Poliklinik der Universitat Erlangen-Nurnberg, Neurologische Klinik Erlangen, Germany Prof. Stephan Zierz, Martin Luther Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat, Universitatsklinik und Poliklinik fur Neurologie Halle, Germany Prof. Reinhard Dengler, Medizinische Hochschule Hannover, Neurologische Klinik Hannover, Germany Prof Gian Domenico Borasio, Interdisziplinares Zentrum fur Palliativmedizin Munchen, Germany Prof. Albert Ludolph, Klinik und Poliklinikfur Neurologie der Universitat Ulm-Univeritatsklinikum Ulm Ulm, Germany Dr. Berthold Schrank, Deutsche Klinik fur Diagnostik, Fachbereich Neurologie Wiesbarden, Germany Italy Prof. Vincenzo Silani, Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto Auxologico Italiano Milano, Italy Dr. Gabriele Mora, Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS Pavia, Italy Prof. Adriano Chio, Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette Torino, Italy Netherlands Prof Marianne de Visser, Academic Medical Centre (AMC) Amsterdam - Dept of Neurology Amsterdam, Netherlands Prof. Leonard H Van Den Berg, University Medical Center Utrecht Utrecht, Netherlands Switzerland Dr. Markus Weber, Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic St. Gallen, Switzerland United Kingdom Prof. Nigel Leigh, Academic Neuroscience Centre London, United Kingdom Prof. Douglas Mitchell, Royal Preston Hospital Preston, United Kingdom Dr. Chris McDermott, Royal Hallamshire Hospital Sheffield, United Kingdom Less <<
NCT03377309 Amyotrophic Lateral Sclerosis Phase 2 Recruiting July 1, 2018 Lebanon ... More >> Johnny S. Salameh Recruiting Beirut, Lebanon, 1107 2020 Contact: Johnny S Salameh, MD    01350000 ext 7359    js73@aub.edu.lb    Principal Investigator: Achraf Makki, MD          Sub-Investigator: Mostafa Hotait, MD Less <<
NCT01371110 - Terminated(no funding) - -
NCT02969759 Sporadic Amyotrophic Lateral S... More >>clerosis Less << Early Phase 1 Not yet recruiting November 2019 -
NCT02424669 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Not Applicable Unknown November 2018 France ... More >> Assistance Publique Hôpitaux de Marseille Recruiting Marseille, France, 13005 Contact: Joelle Micallef       joelle.micallef@ap-hm.fr Less <<
NCT02463825 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 2 Active, not recruiting December 2021 Canada, Alberta ... More >> South Health Campus Calgary, Alberta, Canada, T3M 1M4 Less <<
NCT01569958 Amyotrophic Lateral Sclerosis Phase 2 Unknown April 2016 Italy ... More >> Centro Regionale Malattie Neuromuscolari, Ospedale Clinicizzato "SS. Annunziata" Recruiting Chieti, Italy, 66013 Contact: Margherita Capasso, MD, PhD    00390871358585    neurolab@unich.it    Principal Investigator: Alessandra Lugaresi, MD, PhD          Sub-Investigator: Margherita Capasso, MD,PhD          Azienda Policlinico Università Federico II Not yet recruiting Napoli, Italy, 80131 Principal Investigator: Lucio Santoro, MD          Policlinico Universitario Agostino Gemelli Not yet recruiting Rome, Italy, 00168 Principal Investigator: Vincenzo Di Lazzaro, MD Less <<
NCT03103815 Amyotrophic Lateral Sclerosis Not Applicable Recruiting October 20, 2018 China, Jiangsu ... More >> Wujing People's Hospital Recruiting Changzhou, Jiangsu, China, 213002 Contact: Shidie Zhu, Master    86-519-85579128    513325835@qq.com    Sub-Investigator: Lianming Liao, M.D          Principal Investigator: Maoxin Yue, M.D Less <<
NCT01759784 Amyotrophic Lateral Sclerosis Phase 1 Withdrawn(The stereotaxis can ... More >>be threatful for the patients because of respiratory insufficiency) Less << - Iran, Islamic Republic of ... More >> Royan Institute Tehran, Iran, Islamic Republic of Less <<
NCT01771640 Amyotrophic Lateral Sclerosis Phase 1 Completed - Iran, Islamic Republic of ... More >> Royan Institute Tehran, Iran, Islamic Republic of Less <<
NCT02492516 Amyotrophic Lateral Sclerosis Phase 1 Completed - Iran, Islamic Republic of ... More >> Royan Institute Tehran, Iran, Islamic Republic of Less <<
NCT01371110 Obsessive Compulsive Disorder Phase 1 Phase 2 Terminated(no funding) - United States, New York ... More >> Clinical Research Centers at Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less <<
NCT03408080 Spinocerebellar Ataxias ... More >> Spinocerebellar Ataxia Type 1 Spinocerebellar Ataxia Type 2 Spinocerebellar Ataxia 3 Spinocerebellar Ataxia Type 6 MSA-C Less << Phase 3 Active, not recruiting January 2019 United States, California ... More >> University of California, Los Angeles Los Angeles, California, United States, 90095 Less <<
NCT01759797 Amyotrophic Lateral Sclerosis Phase 1 Completed - Iran, Islamic Republic of ... More >> Royan Institute Tehran, Iran, Islamic Republic of Less <<
NCT00539188 - Terminated(Study terminated du... More >>e to poor subject compliance.) Less << - -
NCT00539513 Obsessive-Compulsive Disorder Phase 2 Terminated(Researchers termina... More >>ted study due to limited enrollment.) Less << - -
NCT03605667 Alzheimer Disease Phase 2 Phase 3 Recruiting February 2, 2020 -
NCT00539513 - Terminated(Researchers termina... More >>ted study due to limited enrollment.) Less << - -
NCT00539188 Borderline Personality Disorde... More >>r Self-Injurious Behavior Less << Phase 2 Terminated(Study terminated du... More >>e to poor subject compliance.) Less << - United States, Connecticut ... More >> Yale OCD Research Clinic New Haven, Connecticut, United States, 06519 Less <<
NCT01753076 - Completed - -
NCT01753076 Amyotrophic Lateral Sclerosis Phase 2 Completed - -
NCT00397423 Amyotrophic Lateral Sclerosis Phase 2 Completed - China, Beijing ... More >> Dongsheng Fan Beijing, Beijing, China, 100083 Less <<
NCT00919555 Amyotrophic Lateral Sclerosis Phase 1 Phase 2 Completed - United States, Arizona ... More >> Phoenix Neurological Associates, LTD Phoenix, Arizona, United States, 85018 Less <<
NCT02306590 Amyotrophic Lateral Sclerosis Not Applicable Unknown April 2018 Germany ... More >> Department of Neurology, University of Ulm Ulm, Baden-Württemberg, Germany, 89081 Department of Neurology, University of Wuerzburg Wuerzburg, Bayern, Germany, 91054 Department of Neurology, University of Rostock Rostock, Mecklenburg-Vorpommern, Germany, D-18147 Department of Neurology, Medical School Hannover Hannover, Niedersachsen, Germany, 30625 Department of Neurology, University of Halle-Wittenberg Halle/Saale, Sachsen-Anhalt, Germany, 06097 Department of Neurology, TU Dresden Dresden, Sachsen, Germany, D-01307 Department of Neurology, University of Jena Jena, Thueringen, Germany, D-07747 Department of Neurology, Humboldt University Berlin, Germany, 13353 Neurologische Universitätsklinik Bergmannsheil Bochum, Germany, 44789 Department für Neurologie - Klinik für Schlafmedizin und Neuromuskuläre Erkrankungen Universitätsklinikum Münster Münster, Germany, 48149 Department of Neurology, DKD HELIOS Klinik Wiesbaden, Germany, 65191 Less <<
NCT00925847 Amyotrophic Lateral Sclerosis Phase 2 Completed - France ... More >> Pitié-Salpêtrière Hospital Paris, France, 75013 Less <<
NCT03456882 Amyotrophic Lateral Sclerosis Phase 2 Recruiting April 30, 2019 United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Sabrina Paganoni    617-726-2000       Contact: Michael Doyle    617-724-7398    mdoyle16@mgh.harvard.edu    Italy Azienda Opsedaliera Universitaria Consorziale Policlinico- Università degli studi di Bari Recruiting Bari, Italy Contact: Simone    080 559 1111       Spedali civili di Brescia Recruiting Brescia, Italy Contact: Filosto    030 39951       ASST Valle Olona Presidio ospedaliero Gallarate Withdrawn Gallarate, Italy IRCCS Azienda Ospedaliera Universitaria San Martino IST Recruiting Genova, Italy Contact: Caponnetto    0105551       Ospedale San Raffaele Recruiting Miano, Italy Contact: Riva    0226433838       Centro Clinico NEMO - Fondazione Serena Onlus Recruiting Milano, Italy Contact: Lunetta    02 914 3371       Presidio Ospedaliero Provinciale - Nuovo Ospedale Civile "S. Agostino Estense" Recruiting Modena, Italy Contact: Mandrioli    059435111       Azienda Ospedaliera Universitaria della Seconda Univ. Degli Studi di Napoli (AOU-SUN) Recruiting Napoli, Italy Contact: Monsurrò    800177780       Azienda Ospedaliero Universitaria Maggiore della Carità Recruiting Novara, Italy Contact: Mazzini    03213731       Azienda Ospedaliera di Padova-Università degli studi di Padova Recruiting Padova, Italy Contact: Sorarù    0498211111       Azienda Ospedaliera Universitaria Policlinico "P Giaccone" Recruiting Palermo, Italy Contact: La Bella    091 655 1111       Istituto Neurologico Nazionale "C. Mondino" Recruiting Pavia, Italy Contact: Ceroni    0382 3801       Azienda Ospedaliero-Universitaria Pisana Active, not recruiting Pisa, Italy POLICLINICO UMBERTO I - Università di Roma "La Sapienza" Not yet recruiting Roma, Italy Contact: Inghilleri    0649971       IRCCS Casa sollievo della Sofferenza Recruiting San Giovanni Rotondo, Italy Contact: Zarrelli    0882 410111       Azienda Ospedaliera Universitaria Senese (AOUS) Recruiting Siena, Italy Contact: Giannini    0577 767676       Azienda Ospedaliera "Santa Maria" di Terni Recruiting Terni, Italy Contact: Spera    0744 2051       Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino. Not yet recruiting Torino, Italy Contact: Chiò    011 633 1633       Azienda Ospedaliera "Card. G. Panico" Not yet recruiting Tricase, Italy Contact: Logroscino    0833 773111 Less <<
NCT03520517 Amyotrophic Lateral Sclerosis ... More >> ALS Lou Gehrig Disease Lou Gehrig's Disease Lou-Gehrigs Disease Motor Neuron Disease, Amyotrophic Lateral Sclerosis Less << Phase 1 Completed - United States, Florida ... More >> Holy Cross Neuroscience Research Institute Fort Lauderdale, Florida, United States, 33334 United States, Nebraska Somnos/Neurology Associates Clinical Research Lincoln, Nebraska, United States, 68506 United States, North Carolina Neurosciences Institute, Neurology - Charlotte Charlotte, North Carolina, United States, 28207 United States, Tennessee Wesley Neurology Clinic Cordova, Tennessee, United States, 38018 United States, Texas Texas Neurology Dallas, Texas, United States, 75214 Less <<
NCT02496767 Amyotrophic Lateral Sclerosis Phase 3 Completed - -
NCT02166944 Amyotrophic Lateral Sclerosis ... More >> ALS Functional Ration Scale TAR-DNA-binding Protein-43 Tamoxifen mTOR Less << Phase 1 Phase 2 Unknown July 2016 Taiwan ... More >> Po-Chih Chen Recruiting New Taipei City, Taiwan Contact: Po-Chih Chen, M.D.    886-2-22490088 ext 8112    euphemus2003@msn.com    Contact: Chaur-Jong Hu, M.D.    886-2-22490088 ext 8112    chaurjongh@tmu.edu.tw    Principal Investigator: Chaur-Jong Hu, M.D. Less <<
NCT03693781 Amyotrophic Lateral Sclerosis Phase 2 Not yet recruiting November 1, 2020 Italy ... More >> Centro Sla, University of Bari Not yet recruiting Bari, Italy Contact: Isabella L Simone, Prof.          Centro Sla, Istituto Auxologico Italiano, University of Milano, Milano Not yet recruiting Milano, Italy Contact: Vincenzo Silani, Prof.          Irccs St. Raffaele Institute of Milano Not yet recruiting Milano, Italy Contact: Nilo Riva, MD          Centro Sla, Ospedale Civile S. Agostino Estense, A.O.U. Modena Not yet recruiting Modena, Italy, 41126 Contact: Jessica Mandrioli, MD    +390593961722       Università della Campania Gianluigi Vanvitelli Not yet recruiting Napoli, Italy Contact: Maria R Monsurrò, MD          Centro Sla, Universita' Di Padova Not yet recruiting Padova, Italy Contact: Gianni Sorarù, MD          Als Centre, "C. Mondino" National Neurological Institute, University of Pavia Not yet recruiting Pavia, Italy Contact: Mauro Ceroni, Prof.          , Neuromuscular Omnicentre Centre, Rome, Catholic University, Rome Not yet recruiting Roma, Italy Contact: Mario Sabatelli, MD          Centro Sla, Universita' Di Torino Not yet recruiting Torino, Italy Contact: Adriano Chiò, Prof. Less <<
NCT01486849 Amyotrophic Lateral Sclerosis Phase 2 Completed - United States, California ... More >> University of California at San Francisco, Fresno Campus, Central California Neurological Institute Fresno, California, United States, 93701 Coordinated Clinical Research La Jolla, California, United States, 92037 University of California at Irvine, ALS and Neuromuscular Center Orange, California, United States, 92868 United States, Connecticut Hospital for Special Care New Britain, Connecticut, United States, 06053 United States, Massachusetts Massachusetts General Hospital, Neurology Clinical Trials Unit Charlestown, Massachusetts, United States, 02129 United States, Missouri Washington University St. Louis, Missouri, United States, 63110 United States, New York Cornell Faculty, Hospital for Special Surgery New York, New York, United States, 10021 United States, North Carolina Duke University School of Medicine, Division of Neurology Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University, Department of Neurology Columbus, Ohio, United States, 43210 United States, Oregon Providence ALS Center Portland, Oregon, United States, 97213 United States, Texas University of Texas Health Science Center, Department of Neurology San Antonio, Texas, United States, 78229 Less <<
NCT02118727 Amyotrophic Lateral Sclerosis ... More >> Frontal Temporal Dementia Less << Phase 2 Recruiting October 2022 United States, Arizona ... More >> Phoenix Neurological Associates Not yet recruiting Phoenix, Arizona, United States, 85018 Contact: Angelina Cooper          Principal Investigator: Todd D Levine, MD          United States, California UC Irvine Not yet recruiting Irvine, California, United States, 92868 Contact: Veronica Martin, CCRC    714-456-7760    vero@uci.edu    Contact: Veena Mathew    714-456-2864    vmathew@uci.edu    Principal Investigator: Tahseen Mozaffar, MD          United States, Kansas University of Kansas Medical Center Recruiting Kansas City, Kansas, United States, 66160 Contact: Sherri Anderson    913-945-9936    sanderson10@kumc.edu    Contact: Andrew Heim    913-945-9926    aheim2@kumc.edu    Principal Investigator: Richard J Barohn, MD          University of Kansas School of Medicine - Wichita Not yet recruiting Wichita, Kansas, United States, 67214 Contact: Trish Steele    316-293-3805    tsteele5@kumc.edu    Principal Investigator: Tiffany Schwasinger-Schmidt, MD          United States, Washington University of Washington Not yet recruiting Seattle, Washington, United States, 98195 Contact: Sharon Downing       sdowning@uw.edu    Contact: Susan Strom, sstrom@uw.edu          Principal Investigator: Michael Weiss, MD Less <<
NCT02136823 Chronic Spinal Cord Injury Not Applicable Unknown - -
NCT01020331 Amyotrophic Lateral Sclerosis Phase 2 Completed - United States, Arizona ... More >> Phoenix Neurological Associates, LTD Phoenix, Arizona, United States, 85018 Less <<
NCT01879241 Amyotrophic Lateral Sclerosis Phase 2 Completed - Germany ... More >> Department of Neurology, University of Ulm Ulm, Baden-Württemberg, Germany, 89081 Department of Neurology, Technische Universität München Muenchen, Bayern, Germany, D-81675 Department of Neurology, Universty of Regensburg Regensburg, Bayern, Germany, D-93053 Department of Neurology, University of Wuerzburg Wuerzburg, Bayern, Germany, 91054 Department of Neurology, Deutsche Klinik für Diagnostik Wiesbaden, Hessen, Germany, D-65191 Department of Neurology, University of Rostock Rostock, Mecklenburg-Vorpommern, Germany, D-18147 Department of Neurology, University of Goettingen Goettingen, Niedersachsen, Germany, D-37073 Department of Neurology, Medical School Hannover Hannover, Niedersachsen, Germany, 30625 Neurologische Universitätsklinik Bergmannsheil Bochum, Nordrhein-Westfalen, Germany, 44789 Department of Neurology, Universty of Muenster Muenster, Nordrhein-Westfalen, Germany, D-48149 Department of Neurology, Universty of Bonn Bonn, Nordrhrein-Westfalen, Germany, D-53105 Department of Neurology, University of Halle-Wittenberg Halle/Saale, Sachsen-Anhalt, Germany, 06097 Department of Neurology, TU Dresden Dresden, Sachsen, Germany, D-01307 Department of Neurology, University of Jena Jena, Thueringen, Germany, D-07747 Department of Neurology, Humboldt University Berlin, Germany, 13353 Less <<
NCT00635960 Amyotrophic Lateral Sclerosis Phase 2 Completed - Italy ... More >> Diparimento di Scienze Neurologiche Naples, Italy, 80131 Istituto Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche Naples, Italy, 80131 Less <<
NCT01910259 Secondary Progressive Multiple... More >> Sclerosis Less << Phase 2 Active, not recruiting July 2018 United Kingdom ... More >> Anne Rowling Regenerative Neurology Clinic, Royal Infirmary of Edinburgh Edinburgh, United Kingdom, EH16 4SA Gartnavel Royal Hospital, 1055 Great Western Road Glasgow, United Kingdom, G12 OXH Brighton and Sussex University Hospitals Haywards Heath, United Kingdom, RH16 4EX St James's University Hospital Leeds, United Kingdom, LS9 7TF The Walton Centre Liverpool, United Kingdom, L9 7LJ The National hospital for Neurology and Neurosurgery, University College London London, United Kingdom, WC1N 3BG The Royal Victoria Infirmary Newcastle, United Kingdom, NE1 4LP Queens Medical Centre Nottingham, United Kingdom, NG7 2UH John Radcliffe Hospital, Oxford University Hospitals NHS Trust Oxford, United Kingdom, OX3 9DU Derriford Hospital Plymouth, United Kingdom, PL6 8DH Royal Hallamshire Hospital Sheffield, United Kingdom, S10 2JF University Hospital of North Staffordshire Stoke-on-Trent, United Kingdom, ST4 7LN Royal Cornwall Hospital Truro, United Kingdom, TR1 3LJ Less <<
NCT00231140 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 2 Terminated - Germany ... More >> Charite University Hospital, Berlin, Germany Berlin, Germany, 13353 Less <<
NCT00876772 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 2 Phase 3 Unknown - Germany ... More >> Charité - Universitätsmedizin, Berlin, Germany Recruiting Berlin, Germany, 13353 Contact: Thomas Meyer, MD    +49.30.450660032    thomas.meyer@charite.de    Contact: Teresa Holm, MD    +49.30.450660218    teresa.holm@charite.de    Principal Investigator: Thomas Meyer, MD Less <<
NCT00690118 Amyotrophic Lateral Sclerosis Phase 2 Terminated(The interim analysi... More >>s showed no tendency in favour of the verum group. Therefore it was decided to stop the study prematurely.) Less << - Germany ... More >> Department of Neurology, University of Ulm Ulm, Baden-Württemberg, Germany, 89081 Department of Neurology and Center for Palliative Medicine, University of Munich Muenchen, Bayern, Germany, D-81366 Department of Neurology, Universty of Regensburg Regensburg, Bayern, Germany, D-93053 Department of Neurology, University of Wuerzburg Wuerzburg, Bayern, Germany, 91054 Department of Neurology, Deutsche Klinik für Diagnostik Wiesbaden, Hessen, Germany, D-65191 Department of Neurology, University of Rostock Rostock, Mecklenburg-Vorpommern, Germany, D-18147 Department of Neurology, University of Goettingen Goettingen, Niedersachsen, Germany, D-37073 Department of Neurology, Medical School Hannover Hannover, Niedersachsen, Germany, 30625 Neurologische Universitätsklinik Bergmannsheil Bochum, Nordrhein-Westfalen, Germany, 44789 Department of Neurology, Universty of Muenster Muenster, Nordrhein-Westfalen, Germany, D-48149 Department of Neurology, Universty of Bonn Bonn, Nordrhrein-Westfalen, Germany, D-53105 Department of Neurology, University of Halle-Wittenberg Halle/Saale, Sachsen-Anhalt, Germany, 06097 Department of Neurology, TU Dresden Dresden, Sachsen, Germany, D-01307 Department of Neurology, University of Jena Jena, Thueringen, Germany, D-07747 Department of Neurology, Humboldt University Berlin, Germany, 13353 Less <<
NCT00013624 Parkinson's Disease Phase 2 Completed - United States, Maryland ... More >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Less <<
NCT03272802 Neuromuscular Diseases Phase 1 Phase 2 Recruiting March 16, 2019 Iran, Islamic Republic of ... More >> EMG Department, Alzahra Hospital Recruiting Isfahan, Iran, Islamic Republic of Less <<
NCT01285583 Amyotrophic Lateral Sclerosis Phase 2 Phase 3 Completed - Belgium ... More >> University Hospital Gasthuisberg - Dept Neurology - Herestraat 49 Leuven, Belgium, 3000 France HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel Bron Cedex, France, 69677 CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement Lille, France, 59037 Centre SLA Limoges - Service de Neurologie Limoges, France, 87042 Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires Marseille, France, 13005 Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac Montpellier, France, 34295 CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA Nice, France, 06202 Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux Paris, France, 75013 Germany Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen Berlin, Germany, 13353 Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg Halle, Germany, 06097 Neurologische Klinik Medizinische Hochschule Hannover, Germany, D-30623 Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik Ulm, Germany, 89081 Spain Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10 Madrid, Spain, 28029 United Kingdom King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry London, United Kingdom, SE58AF Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences Sheffield, United Kingdom, S10 2RX Less <<
NCT03039673 Amyotrophic Lateral Sclerosis Phase 2 Recruiting June 2021 France ... More >> CHRU de Lille - Hôpital Roger Salengro Recruiting Lille, France, 59037 Principal Investigator: Dr Véronique Danel, MD, PhD          CHU de Limoges - Hôpital Dupuytren Recruiting Limoges, France, 87042 Principal Investigator: Philippe Couratier, MD, PhD          HCL - Hôpital Neurologique P. Wertheimer Recruiting Lyon, France, 69677 Principal Investigator: Dr Emilien Bernard, MD, PhD          APHM - Hôpital de la Timone Recruiting Marseille, France, 13385 Principal Investigator: P Shahram Attarian, MD, PHD          CHRU de Montpellier - Hôpital Gui de Chauliac Recruiting Montpellier Cedex 5, France, 34295 Principal Investigator: William Camu, MD, PhD          CHU de Nice - Hôpital Pasteur Recruiting Nice, France, 06002 Principal Investigator: Hélène Soriani, MD, PhD          APHP - Groupe Hospitalier Pitié-Salpetrière Recruiting Paris Cedex 13, France, 75651 Principal Investigator: François Salachas, MD          CENTRE HOSPITALIER DE SAINT BRIEUC - Hôpital Yves Le Foll Recruiting Saint Brieuc, France, 22027 Principal Investigator: Kolev Ivan, MD,PhD          CHU de Strasbourg - Hôpital de Hautepierre Recruiting Strasbourg, France, 67098 Principal Investigator: Marie FLEURY-LESAUNIER, MD,PhD          CHRU de Tours - Hôpital Bretonneau Recruiting Tours, France, 37044 Principal Investigator: Philippe Corcia, MD, PhD          United Kingdom Trafford Centre for Biomedical Research Recruiting Brighton, United Kingdom, BN1 9RY Principal Investigator: P Nigel Leigh, MD, PhD          Institute of Neurological Sciences, Queen Elizabeth University Hospital Recruiting Glasgow, United Kingdom, G514TF Principal Investigator: George Gorrie, MD,PhD          North-East London and Essex MND Regional Care Centre Recruiting London, United Kingdom, E1 4NS Principal Investigator: Andrea Malaspina, MD, PhD          King's MND Care and Research Centre Recruiting London, United Kingdom, SE5 8AF Principal Investigator: Ammar Al-Chalabi, MD, PhD          Centre for Neuromuscular Diseases - National Hospital of Neurology Recruiting London, United Kingdom, WC1N 3BG Principal Investigator: Dr Nikhil SHARMA, MD, PhD          Sheffield Care and Research Centre Recruiting Sheffield, United Kingdom, S10 2JF Principal Investigator: Pamela J Shaw, MD, PhD Less <<
NCT01277315 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 2 Unknown - Germany ... More >> Charité University Hospital Recruiting Berlin, Germany, 13353 Contact: Thomas Meyer, MD    +49.30.450660032    thomas.meyer@charite.de    Contact: Teresa Holm, MD    +49.30.450660218    teresa.holm@charite.de Less <<
NCT02645461 Amyotrophic Lateral Sclerosis Not Applicable Completed - -
NCT00353665 Amyotrophic Lateral Sclerosis Phase 2 Phase 3 Completed - Portugal ... More >> Department of Neurology - Hospital de Santa Maria Lisbon, Portugal, 1649-028 Less <<
NCT00403104 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 2 Completed - Austria ... More >> L. Boltzmann Forschungsinstitut, Neurologische Abteilung, Kaiser Franz Josef Hospital, Wien Wien, Austria, 1100 Belgium UCL Saint-Luc Brussels, Belgium UZ Leuven Leuven, Belgium, 3000 France Hopital Roger Salengro - Clinique Neurologique, Neurologie A Lille Cedex, France, 59037 Hopital Duruytren Limoges Cedex, France, 87042 Hopital de la Timone Marseille, France, 13005 Hopital de Chauliac Montpellier cedex 5, France, 34295 Hopital l-Archet 1 Nice cedex 3, France, 06202 Hopital LaPitie Salpetriere Paris, France, 75013 Germany Charite Campus Virchow, ALS Ambulanz Berlin, Germany, 13353 Neurologische Universitatsklinik Bergmannsheil Bochum, Germany, 44789 Poliklinik der Universitat Erlangen-Nurnberg, Neurologische Klinik Erlangen, Germany, 91054 Martin-Luther-Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat, Universitatsklinik und Poliklinik fur Neurologie Halle, Germany, 06120 Medizinische Hochschule Hannover, Neurologische Klinik Hannover, Germany, 30623 Interdisziplinares Zentrum fur Palliativmedizin Munchen, Germany Klinik und Poliklinik fur Neurologie der Universitat Ulm-Universitatsklinikum Ulm Ulm, Germany, 89081 Deutsche Klinik fur Diagnostik, Fachbereich Neurologie Wiesbaden, Germany, 65191 Italy Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto Auxologico Italiano Milano, Italy, 20149 Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS Pavia, Italy, 27100 Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette Torino, Italy, 10126 Netherlands Academic Medical Centre (AMC) Amsterdam - Dept of Neurology Amsterdam, Netherlands University Medial Center Utrecht Utrecht, Netherlands Switzerland Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic St. Gallen, Switzerland, 9007 United Kingdom Academic Neuroscience Centre London, United Kingdom Royal Preston Hospital Preston, United Kingdom, PR29HT University of Sheffield - Academic Neurology Unit Sheffield, United Kingdom Less <<
NCT01709149 Amyotrophic Lateral Sclerosis Phase 2 Completed - -
NCT00419003 Major Depression Phase 4 Completed - United States, New York ... More >> Mount Sinai School of Medicine New York, New York, United States, 10029 Less <<
NCT00903214 Breast Cancer Phase 1 Withdrawn(Funding ended) - -
NCT00026052 Depression Phase 2 Completed - United States, Maryland ... More >> National Institute of Mental Health (NIMH) Bethesda, Maryland, United States, 20892 Less <<
NCT00211224 Multiple System Atrophy|Progre... More >>ssive Supranuclear Palsy Less << PHASE3 TERMINATED 2025-11-04 Institute of Psychiatry, King'... More >>s College London, London, SE58AF, United Kingdom Less <<
NCT00818389 Amyotrophic Lateral Sclerosis Phase 2 Phase 3 Terminated(NINDS DSMB recommen... More >>ded trial be terminated for futility after reviewing an interim analysis of 84 subjects.) Less << - -
NCT00419003 - Completed - -
NCT00667901 Melanoma (Skin) Phase 1 Terminated(All enrollment, tre... More >>atment, follow-up & data analysis completed) Less << - United States, New Jersey ... More >> Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States, 08903 Less <<
NCT00283309 Mood Memory D... More >>eficit Less << Phase 4 Terminated(Study finished enro... More >>llment but data was never sent for publishing.) Less << - United States, Texas ... More >> UT Southwestern Dallas, Texas, United States, 75390 Less <<
NCT01018056 Tourette Syndrome Phase 4 Completed - United States, Maryland ... More >> Johns Hopkins University Baltimore, Maryland, United States, 21287 Less <<
NCT01018056 - Completed - -
NCT02588677 Amyotrophic Lateral Sclerosis ... More >>(ALS) Less << Phase 2 Phase 3 Completed - Spain ... More >> Hospital Carlos III Madrid, Spain, 28029 Less <<
NCT03537807 Amyotrophic Lateral Sclerosis|... More >>ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis Less << NO_LONGER_AVAILABLE - -
NCT00277602 Huntington Disease PHASE3 COMPLETED 2025-07-04 -
NCT02238626 Amyotrophic Lateral Sclerosis Phase 2 Completed - United States, North Carolina ... More >> Carolinas Healthcare System, Dept. of Neurology Charlotte, North Carolina, United States, 28232-2861 Less <<
NCT00818389 - Terminated(NINDS DSMB recommen... More >>ded trial be terminated for futility after reviewing an interim analysis of 84 subjects.) Less << - -
NCT01019967 - Terminated - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00868166 Amyotrophic Lateral Sclerosis Phase 2 Phase 3 Completed - Belgium ... More >> University Hospital Gasthuisberg - Dept Neurology - Herestraat 49 Leuven, Belgium, 3000 France HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel Bron Cedex, France, 69677 CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement Lille, France, 59037 Centre SLA Limoges - Service de Neurologie Limoges, France, 87042 Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires Marseille, France, 13005 Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac Montpellier, France, 34295 CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA Nice, France, 06202 Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux Paris, France, 75013 Germany Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen Berlin, Germany, 13353 Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg Halle, Germany, 06097 Neurologische Klinik Medizinische Hochschule Hannover, Germany, D-30623 Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik Ulm, Germany, 89081 Spain Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10 Madrid, Spain, 28029 United Kingdom King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry London, United Kingdom, SE58AF Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences Sheffield, United Kingdom, S10 2RX Less <<
NCT00542412 Amyotrophic Lateral Sclerosis PHASE4 COMPLETED 2025-12-04 Sanofi-Aventis, Laval, Quebec,... More >> Canada Less <<
NCT03127267 Amyotrophic Lateral Sclerosis Phase 3 Not yet recruiting May 2024 -
NCT00501943 Multiple Sclerosis Phase 2 Completed - United States, California ... More >> UCSF MS Center , 675 Nelson Rising Lane, Suite 221 San Francisco, California, United States, 94158 Less <<
NCT00501943 - Completed - -
NCT00054704 Bipolar Disorder Phase 2 Terminated(Placebo was better ... More >>than active drug.) Less << - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00376220 Bipolar Disorder Phase 2 Completed - United States, Maryland ... More >> Johns Hopkins Baltimore, Maryland, United States, 21205 Less <<
NCT00376220 - Completed - -
NCT00805493 Bipolar Disorder|Anxiety Disor... More >>ders|Bipolar Affective Disorder|Bipolar Depression Less << PHASE2 TERMINATED 2025-06-12 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00805493 Bipolar Disorder|Anxiety Disor... More >>ders|Bipolar Affective Disorder|Bipolar Depression Less << PHASE2 TERMINATED 2025-06-12 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00202397 Hereditary Ataxia ... More >> Multiple Sclerosis Cerebellar Ataxia Less << Phase 2 Completed - Italy ... More >> S.Andrea Hospital - University of Rome "La Sapienza" Rome, Italy, 00100 Less <<
NCT00375050 Schizophrenia ... More >> Schizoaffective Less << Not Applicable Suspended September 2018 United States, Connecticut ... More >> Yale Department of Psychiatry New Haven, Connecticut, United States, 06519 Less <<
NCT00774423 SMA PHASE2|PHASE3 COMPLETED 2025-12-11 Hopital Raymond Poincare, Garc... More >>hes, 92380, France Less <<
NCT01703117 Alzheimer's Disease Phase 2 Recruiting November 2019 United States, New York ... More >> The Rockefeller University Recruiting New York, New York, United States, 10065 Contact: RU Cares    800-782-2737    RUCares@rockefeller.edu Less <<
NCT01597518 Spinal Cord Injury Phase 2 Phase 3 Recruiting May 2025 -
NCT00876889 Spinal Cord Injury COMPLETED 2025-04-12 University of Miami, Miami, Fl... More >>orida, 33136, United States|University of Louisville Health Sciences Center, Louisville, Kentucky, 40205, United States|University of Maryland Medical Center, Baltimore, Maryland, 21201, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|The Methodist Hospital, Houston, Texas, 77030, United States|The University of Texas, Houston, Texas, 77030, United States|University of Virginia Health System, Charlottesville, Virginia, 22903, United States|University of Toronto/Toronto Western Hospital, Toronto, Ontario, M5T-2S8, Canada Less <<
NCT00054704 - Terminated(Placebo was better ... More >>than active drug.) Less << - -
NCT00251303 Obsessive-Compulsive Disorder ... More >> Autism Spectrum Disorder Autism Asperger Disorder Developmental Disorder Less << Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00523718 Obsessive-compulsive Disorder ... More >> Ocd Less << Phase 2 Completed - United States, Connecticut ... More >> Yale OCD Research Clinic New Haven, Connecticut, United States, 06508 Less <<
NCT00523718 - Completed - -
NCT00251303 - Completed - -
NCT00544544 Bipolar Depression COMPLETED 2025-07-09 McLean Hospital, Belmont, Mass... More >>achusetts, 02478, United States Less <<
NCT00544544 Bipolar Depression COMPLETED 2025-07-09 McLean Hospital, Belmont, Mass... More >>achusetts, 02478, United States Less <<
NCT00866840 Melanoma (Skin) Phase 2 Completed - United States, New Jersey ... More >> Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States, 08903 Less <<
NCT02859792 Spinal Cord Injury Phase 2 Not yet recruiting May 2021 France ... More >> Assistance Publique Hopitaux de Marseille Not yet recruiting Marseille, France, 13354 Contact: OLIVIER BLIN       olivier.blin@ap-hm.fr    Principal Investigator: jean-michel VITON Less <<
NCT01257828 Cervical Spondylotic Myelopath... More >>y Less << Phase 3 Completed - -
NCT01703039 Major Depressive Disorder Phase 2 Recruiting September 2019 United States, Massachusetts ... More >> Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Molly O'Reilly, MA       RAPID@PARTNERS.ORG    Contact: David Wolfe, MD       DWOLFE@PARTNERS.ORG    Principal Investigator: David J Wolfe, MD, MPH Less <<
NCT01018836 Metastatic Cancer ... More >> Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Terminated(Slow accrual) - United States, New Jersey ... More >> Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States, 08903 Less <<
NCT01303341 Advanced Malignant Solid Neopl... More >>asm Recurrent Melanoma Refractory Malignant Solid Neoplasm Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Less << Phase 1 Active, not recruiting - United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Less <<
NCT01104649 Cerebellar Ataxia Phase 2 Phase 3 Completed - Italy ... More >> Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, II Faculty of Medicine, "Sapienza" University of Rome Rome, Italy, 00139 Less <<
NCT00895752 Fragile X Syndrome PHASE4 COMPLETED 2025-07-10 Riley Child and Adolescent Psy... More >>chiatry Clinic - Riley Hospital for Children, Indianapolis, Indiana, 46202, United States Less <<
NCT01204918 - Completed - -
NCT01204918 Depression Phase 2 Completed - United States, Connecticut ... More >> Yale University, Yale Depression Research Program New Haven, Connecticut, United States, 06511 United States, Massachusetts Massachussettes General Hospital, Depression Clinical and Research Center Boston, Massachusetts, United States, 02114 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 Less <<
NCT00895752 Fragile X Syndrome PHASE4 COMPLETED 2025-07-10 Riley Child and Adolescent Psy... More >>chiatry Clinic - Riley Hospital for Children, Indianapolis, Indiana, 46202, United States Less <<
NCT01661855 Autism Spectrum Disorders Phase 2 Completed - Canada, Ontario ... More >> Offord Centre for Child Studies Hamilton, Ontario, Canada, L8S 4K1 Lawson Health Research Institute London, Ontario, Canada, N6A 5W9 Holland Bloorview Kids Rehabilitation Hospital Toronto, Ontario, Canada, M4G 1R8 Less <<
NCT03457753 ALS Phase 2 Withdrawn(The Sponsor stopped ... More >>the study due to a change in study plans) Less << October 2018 United States, Texas ... More >> Texas Neurology, P.A. Dallas, Texas, United States, 75214 Less <<
NCT03017508 Social Anxiety Disorder ... More >> Performance Anxiety Less << Phase 2 Phase 3 Recruiting October 2019 United States, Connecticut ... More >> Connecticut Mental Health Center Recruiting New Haven, Connecticut, United States, 06508 Contact: Michael H. Bloch, MD, MS    203-785-7683    michael.bloch@yale.edu Less <<
NCT02081027 Autism Spectrum Disorders Phase 2 Phase 3 Completed - United States, Ohio ... More >> Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Less <<
NCT03679975 Amyotrophic Lateral Sclerosis Phase 2 Enrolling by invitation November 1, 2018 United States, Florida ... More >> University of Florida Center for Movement Disorders & Neuroscience Gainesville, Florida, United States, 32607 Less <<
NCT03347344 Spinocerebellar Ataxia Type 2 Phase 3 Recruiting January 17, 2019 France ... More >> Durr Recruiting Paris, France, 75013 Contact: Petit Elodie Less <<
NCT03660917 SCA7 Phase 2 Phase 3 Not yet recruiting January 1, 2021 Italy ... More >> Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome Rome, Italy, 00139 Less <<
NCT03722680 Oxaliplatin-induced Peripheral... More >> Neuropathy Less << Phase 2 Not yet recruiting August 31, 2022 -
NCT02155829 PTSD Phase 1 Phase 2 Unknown - United States, Maryland ... More >> Walter Reed National Military Medical Center Recruiting Bethesda, Maryland, United States, 20814 Contact: Patricia T Spangler, Ph.D.    240-620-4076    patricia.spangler.ctr@usuhs.edu    Contact: Jennifer Bornemann, LCSW-C    301-295-3485    jennifer.bornemann@usuhs.edu    Principal Investigator: David M Benedek, MD          United States, New York Syracuse VA Medical Center, Center for Integrated Healthcare (116C) Recruiting Syracuse, New York, United States, 13210 Contact: Shannon McKenzie    315-425-3954    Shannon.McKenzie@va.gov    Contact: Kyle Possemato, PhD    315-425-3551    Kyle.Possemato@va.gov    Principal Investigator: Kyle Possemato, PhD Less <<
NCT02019940 PTSD PHASE1 COMPLETED 2025-01-20 Clinical Neuroscience Division... More >>, National Center for PTSD, West Haven, Connecticut, 06516, United States Less <<
NCT02796755 Inflammation ... More >>Fatigue Less << Phase 4 Recruiting November 2019 United States, Georgia ... More >> Emory University Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Andrew H Miller, MD    404-727-8260    amill02@emory.edu    Contact: Bobbi Woolwine, LCSW    404-712-9620    bwoolwi@emory.edu Less <<
NCT04630444 Posttraumatic Stress Disorder EARLY_PHASE1 COMPLETED 2019-03-16 McLean Hospital, Belmont, Mass... More >>achusetts, 02478, United States Less <<
NCT06270108 Treatment-resistant Schizophre... More >>nia|Treatment-responsive Schizophrenia|Healthy Controls Less << EARLY_PHASE1 RECRUITING 2024-12-31 Institute of Psychiatry, Psych... More >>ology and Neuroscience, London, SE5 8AB, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.27mL

0.85mL

0.43mL

21.35mL

4.27mL

2.13mL

42.70mL

8.54mL

4.27mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories